Specifications
- Purity
- ≥98% (HPLC)
- Appearance
- White powder
- Identity
- 1H-NMR
Properties
- Solvents
- water
- Density
- 1.264 g/cm3
Documentation
- Safety Data Sheet (SDS)
- CDX P0167 MSDS.pdf
Available from stock
Parecoxib
- SKU
- P0167
Category: API's & Intermediates
- Synonyms
- N-[[4-(5-Methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide , Dynastat , SC-69124
- 198470-84-7
- CAS-Number
- C19H18N2O4S
- Molecular Formula
- 370.42
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- +4°C
- Long Term Storage
- -20°C
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at -20°C.
- Hazard statements
- H361d, H373
- Precautionary statements
- P281
- GHS Symbol
- GHS08
- Signal word
- Warning
- Transportation
- Not dangerous goods
- Description
- Potent and selective COX-2 inhibitor. Water-soluble amide prodrug of the cyclooxygenase II (COX-2) selective, non-steroidal anti-inflammatory drug (NSAID) valdecoxib. Has anti-inflammatory, analgesic, and antipyretic activities. Upon administration, parecoxib is hydrolyzed by hepatic carboxyesterases to its active form, valdecoxib.
- Smiles
- O=C(CC)NS(=O)(C1=CC=C(C2=C(C)ON=C2C3=CC=CC=C3)C=C1)=O
- InChi Key
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N
- References
- (1) J.J. Talley, et al. , J. Med. Chem. 43, 1661 (2000) , (2) S.S. Padi, et al. , Eur. J. Pharmacol. 491, 69 (2004) , (3) A.B. Reksidler, et al. , Eur. J. Pharmacol. 560, 163 (2007) , (4) A. Abbate, et al. , J. Cardiovasc. Pharmacol. 49, 416 (2007) , (5) H. Schroeder, et al. , Neurochem. Int. 58, 9 (2011) , (6) Z. Ye, et al. , Neurochem. Res. 37, 321 (2012) , (7) S.J.Chong, et al. , Int. J. Infλ 2014, 972645 (2014)
- InChi
- InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)
Potent and selective COX-2 inhibitor. Water-soluble amide prodrug of the cyclooxygenase II (COX-2) selective, non-steroidal anti-inflammatory drug (NSAID) valdecoxib. Has anti-inflammatory, analgesic, and antipyretic activities. Upon administration, parecoxib is hydrolyzed by hepatic carboxyesterases to its active form, valdecoxib.
Additional information
| Synonyms | N-[[4-(5-Methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide, Dynastat, SC-69124 |
|---|---|
| Purity | ≥98% (HPLC) |
| Appearance | White powder |
| CAS-Number | 198470-84-7 |
| Molecular Formula | C19H18N2O4S |
| Molecular Weight | 370.42 |
| Identity | 1H-NMR |
| Solvents | water |
| Density | 1.264 g/cm3 |
| Smiles | O=C(CC)NS(=O)(C1=CC=C(C2=C(C)ON=C2C3=CC=CC=C3)C=C1)=O |
| InChi Key | TZRHLKRLEZJVIJ-UHFFFAOYSA-N |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Hazard statements | H361d, H373 |
| Precautionary statements | P281 |
| GHS Symbol | GHS08 |
| Signal word | Warning |
| Transportation | Not dangerous goods |
| References | (1) J.J. Talley, et al., J. Med. Chem. 43, 1661 (2000), (2) S.S. Padi, et al., Eur. J. Pharmacol. 491, 69 (2004), (3) A.B. Reksidler, et al., Eur. J. Pharmacol. 560, 163 (2007), (4) A. Abbate, et al., J. Cardiovasc. Pharmacol. 49, 416 (2007), (5) H. Schroeder, et al., Neurochem. Int. 58, 9 (2011), (6) Z. Ye, et al., Neurochem. Res. 37, 321 (2012), (7) S.J.Chong, et al., Int. J. Infλ 2014, 972645 (2014) |
| InChi | InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22) |
| Quantity | 25 mg, Bulk |
